A Double Blind, Randomized, Active-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Gastric Ulcer
Phase of Trial: Phase III
Latest Information Update: 02 Jan 2017
At a glance
- Drugs Tegoprazan (Primary) ; Lansoprazole
- Indications Gastric ulcer; Gastro-oesophageal reflux
- Focus Registrational; Therapeutic Use
- Sponsors CJ HealthCare
- 28 Dec 2016 Planned End Date changed from 1 Nov 2017 to 1 Mar 2018.
- 28 Dec 2016 Planned primary completion date changed from 1 May 2017 to 1 Dec 2017.
- 28 Dec 2016 Status changed from not yet recruiting to recruiting.